Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia
The aims of this observational study are to identify the primary BPH symptoms responsible for
 the patients to consult a urologic practice, resulting in the prescription of ALNA®, to
 assess the clincial efficacy on an improved occupational performance of the patients being
 still employed. Additionally to obtain relevant information for the 5-year report of
 experience with this product according to the requirements in § 49, para 6 of the German
 Medicines Act.
Inclusion Criteria:

 -  Patients suffering from symptomatic benign prostatic hyperplasia (BPH) symptoms and
 receiving ALNA® treatment are to be included in the observation according to the
 prescribing information

 Exclusion Criteria:

 No exclusion criteria is defined, prescribing information is to be considered